Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820343 | 0.85 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4USP30HTR2A | |
| SCHEMBL13085465 | 0.81 | QDPR (0.59) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL24877484 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4USP30HTR2A | |
| SCHEMBL15765688 | 0.77 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL16649755 | 0.77 | HTR2A (0.45) | SLC6A2SLC6A3SLC6A4HTR2AHTR2C | |
| SCHEMBL18711720 | 0.77 | USP30 (0.50) | SLC6A2SLC6A3SLC6A4USP30 | |
| SCHEMBL16649448 | 0.77 | HTR2A (0.45) | SLC6A2SLC6A3SLC6A4HTR2AHTR2C | |
| SCHEMBL808710 | 0.76 | HTR2A (0.46) | SLC6A2SLC6A3SLC6A4USP30HTR2A | |
| SCHEMBL29389392 | 0.76 | HTR2A (0.46) | SLC6A2SLC6A3SLC6A4USP30HTR2A | |
| Methyl Alcohol SCHEMBL27955336 | 0.75 | HTR2A (0.42) | SLC6A2SLC6A3SLC6A4USP30HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283425-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| EP-3519385-B1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014912-B2 | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 | USP30, USP39, USP28 | SLC6A2 4696/4885SLC6A3 4618/4885SLC6A4 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.